CMS Prior Authorization

A new CMS rule - CMS-1717-FC - requires a new prior authorization process for neurotoxin injections for patients in the hospital outpatient setting. Since the rule's implementation on July 1, many movement disorders patients have experienced new challenges accessing their treatments, including delays or denials. Meanwhile, health care providers are seeing new paperwork burdens and barriers in getting the right care for their patients.

Policymakers need to hear from you! Tell CMS and your Member of Congress this policy needs to be updated. Weigh in through our survey, write your legislator and share your experience online.



TAKE SURVEY

 
MDPC Survey.png
 

This survey explores how a new rule from the Centers for Medicare and Medicaid Services impacts access to care for people living with movement disorders and other conditions. The rule requires prior authorization before any neurotoxin injection is provided in an outpatient hospital setting.

Survey responses will be used to provide input to members of Congress so they are made aware of the rule’s adverse effects.  

Contact Your Legislator

 
MDPC Contact.png
 

Congress must act to ask CMS to suspend this rule immediately until such a time as it can be implemented appropriately and without causing delays in care. Without immediate action, patients and providers will continue to face barriers in accessing their appropriate, effective treatments.

Feel free to edit the letter and share your personal experience with lawmakers.

Join the Conversation

 
MDPC Conversation.png
 

Tweet these messages to join the conversation on social media.

  • A new CMS rule instituting prior authorization for neurotoxin injections is delaying care for #movementdisorders patients. @CMSgov should suspend this policy until it can be implemented without delays for patients. Learn more & take action: https://bit.ly/34AJ62o

  • A new CMS rule implementing prior authorization for neurotoxins has negatively impacted patients by delaying or denying them access to the treatments their provider has prescribed. @cmsgov should protect access by suspending this rule. Learn more: https://bit.ly/34AJ62o

  • .@CMSgov's decision to institute new prior authorizations for botulinum toxin injections has led to unintended health outcomes for people living with #movementdisorders. Ask your representative to urge CMS to suspend this policy here: https://bit.ly/3deUyob

  • .@CMSgov’s new prior authorization rule is creating barriers to access for people living with movement disorders like #dystonia. Let your voice be heard in this brief survey: https://bit.ly/30EyBtC